HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AR C124910XX

active metabolite of ticagrelor

Also Known As:

AR-C124910XX

Networked: 9 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        AR C124910XX: 9
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - AR C124910XX: 9
  - Ribonucleosides: 49
    - Adenosine: 12431
      - AR C124910XX: 9

Experts

1.	Storey, Robert F: 3 articles (05/2017 - 08/2015)
2.	Buszko, Katarzyna: 2 articles (01/2022 - 01/2017)
3.	Kubica, Jacek: 2 articles (01/2022 - 01/2017)
4.	Marszałł, Michał P: 2 articles (01/2022 - 01/2017)
5.	Navarese, Eliano P: 2 articles (01/2022 - 01/2017)
6.	Sikora, Adam: 2 articles (01/2022 - 01/2017)
7.	Sikora, Joanna: 2 articles (01/2022 - 01/2017)
8.	Sobczak, Przemysław: 2 articles (01/2022 - 01/2017)
9.	Hamrén, Bengt: 2 articles (10/2019 - 05/2017)
10.	Husted, Steen: 2 articles (09/2016 - 08/2015)

Related Diseases

1.	Acute Coronary Syndrome 09/01/2016 - "Data from two studies in patients with acute coronary syndromes with large amounts of pharmacokinetic (PK) data (phase IIb DISPERSE-2 study (n = 609)); phase III PLATO PK substudy (n = 6,381)), along with non-linear mixed effects modeling software, were used to develop population PK models for ticagrelor and its metabolite, AR-C124910XX, and to evaluate the impact of demographic and clinical factors on the PK of ticagrelor and AR-C124910XX. "
2.	Myocardial Infarction 09/01/2019 - "This validated method was effectively used in the determination of ticagrelor and its active metabolite, AR-C124910XX, in plasma samples from patients with myocardial infarction." 05/01/2017 - "The population pharmacokinetics of ticagrelor and its active metabolite AR-C124910XX were characterized following ticagrelor 60 mg or 90 mg twice daily oral long-term treatment in 4,426 patients with a history of myocardial infarction. "
3.	Body Weight (Weight, Body) 10/01/2019 - "An allometric body weight relationship between ticagrelor and AR-C124910XX clearances and volumes of distribution was used. " 05/01/2017 - "Both ticagrelor and AR-C124910XX CL/F were independently influenced by body weight, sex, age, smoking, and Japanese ethnicity. "
4.	AIDS-Related Complex (ARC) 01/01/2021 - "Ticagrelor, a direct-acting P2Y12-receptor antagonist, is easily absorbed and partly metabolized to major AR-C124910XX metabolite (ARC). " 08/01/2015 - "Ticagrelor, a direct-acting P2Y12-receptor antagonist, is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). "
5.	Non-ST Elevated Myocardial Infarction 10/01/2020 - "There were no significant differences for drug concentration, Cmax, or AUC of ticagrelor and AR-C124910XX between patients with STEMI and NSTEMI (P > 0.05). " 01/01/2017 - "Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. " 01/01/2017 - "During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ngh/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ngh/mL; p = 0.027). "

Related Drugs and Biologics

1.	Ticagrelor
2.	AR C124910XX
3.	Naloxone (Narcan)
4.	Morphine (MS Contin)